Odyssey Therapeutics Reports Q1 2026 Results, Confirms Strong Liquidity Post-IPO, Extending Cash Runway into H2 2028
Summary
Odyssey Therapeutics reported Q1 2026 results, highlighting a strong cash position and extended runway into H2 2028 following its recent IPO and private placement, which raised $288.7 million.
Key Events
-
Successful IPO and Private Placement
The company completed its initial public offering (IPO) and a concurrent private placement in May and June 2026, raising aggregate net proceeds of $288.7 million. This includes 15.5 million shares sold in the IPO at $18.00 per share, a $23.3 million private placement, and an additional $10.0 million from underwriters' option exercise.
-
Extended Cash Runway
With existing cash, cash equivalents, and marketable securities of $175.7 million as of March 31, 2026, combined with the IPO proceeds, the company expects to fund operations into the second half of 2028, resolving prior going concern conditions.
-
Q1 2026 Financial Performance
Odyssey Therapeutics reported a net loss of $38.3 million for the three months ended March 31, 2026, compared to $38.4 million for the same period in 2025. Collaboration revenue decreased to zero as prior agreements concluded.
-
Reverse Stock Split Effected
On May 1, 2026, the company effected a 1-for-9.7170 reverse stock split, retroactively adjusting all share and per-share information in the financial statements.
Analysis
This quarterly report provides the financial backdrop to Odyssey Therapeutics' recent public listing and ongoing clinical development. The company successfully completed its IPO and a concurrent private placement in May and June 2026, raising significant net proceeds of $288.7 million. This capital infusion has resolved prior going concern doubts and is expected to fund operations into the second half of 2028, providing crucial runway for its clinical-stage pipeline, including the lead candidate OD-001 which recently reported positive proof-of-concept data. While the company continues to incur net losses, this substantial capital raise is a critical positive for a clinical-stage biopharmaceutical company.
At the time of this filing, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.